Tarsus Pharmaceuticals (TARS) Revenue & Revenue Breakdown
Tarsus Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$182.95M
Latest Revenue (Q)
$78.33M
Main Segment (Y)
Product
Tarsus Pharmaceuticals Revenue by Period
Tarsus Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $182.95M | 948.62% |
2023-12-31 | $17.45M | -32.42% |
2022-12-31 | $25.82M | -54.73% |
2021-12-31 | $57.03M | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Tarsus Pharmaceuticals generated $182.95M in revenue during NA 2024, up 948.62% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Tarsus Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2025-03-31 | $78.33M | 17.96% |
2024-12-31 | $66.41M | 38.01% |
2024-09-30 | $48.12M | 17.90% |
2024-06-30 | $40.81M | 47.80% |
2024-03-31 | $27.61M | 111.18% |
2023-12-31 | $13.08M | 598.88% |
2023-09-30 | $1.87M | -87.75% |
2023-06-30 | $15.28M | 511.08% |
2023-03-31 | $2.50M | -75.00% |
2022-12-31 | $10.00M | 100.00% |
2022-09-30 | - | -100.00% |
2022-06-30 | $15.28M | 2734.32% |
2022-03-31 | $539.00K | 59.47% |
2021-12-31 | $338.00K | -72.74% |
2021-09-30 | $1.24M | -94.37% |
2021-06-30 | $22.02M | -34.14% |
2021-03-31 | $33.43M | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
Tarsus Pharmaceuticals generated $78.33M in revenue during Q1 2025, up 17.96% compared to the previous quarter, and up 599.07% compared to the same period a year ago.
Tarsus Pharmaceuticals Revenue Breakdown
Tarsus Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|---|
Product | $180.06M | $14.73M | - | - |
License Fees and Collaboration | $2.89M | $2.72M | $955.00K | $2.08M |
Collaboration Revenue | - | - | $1.92M | $3.96M |
License and Service | - | - | $23.89M | $53.07M |
Tarsus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (98.42%), and License Fees and Collaboration (1.58%).
Quarterly Revenue by Product
Product/Service | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product | $78.33M | $107.22M | $48.12M | $24.72M | $13.08M | $1.65M | - | - | - | - | - | - | - |
License And Collaboration | - | - | - | $2.89M | $218.00K | $2.50M | $522.00K | $33.00K | $65.00K | $737.00K | $1.30M | - | - |
License and Service | - | - | - | - | - | - | - | $10.00M | $13.89M | - | $708.00K | $19.05M | $33.31M |
Collaboration | - | - | - | - | - | - | - | - | $1.38M | $539.00K | $532.00K | $2.97M | $121.00K |
Tarsus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Product (100.00%).
Tarsus Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
---|---|---|---|---|---|---|---|
License And Collaboration | $2.50M | $522.00K | $33.00K | $65.00K | $737.00K | $1.30M | - |
License and Service | - | $10.00M | $13.89M | - | $708.00K | $19.05M | $33.31M |
Collaboration | - | - | $1.38M | $539.00K | $532.00K | $2.97M | $121.00K |
Tarsus Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: License And Collaboration (100.00%).
Tarsus Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | $182.95M | $78.33M |
PHAT | Phathom Pharmaceuticals | $55.25M | $28.52M |
IVA | Inventiva | $17.48M | $2.73M |
PRAX | Praxis Precision Medicines | $8.55M | - |
VRCA | Verrica Pharmaceuticals | $7.57M | $344.00K |
INBX | Inhibrx Biosciences | $200.00K | $100.00K |
FDMT | 4D Molecular Therapeutics | - | $1.00K |
EWTX | Edgewise Therapeutics | - | - |
VIGL | Vigil Neuroscience | - | - |